{"id":634144,"date":"2023-01-16T16:28:01","date_gmt":"2023-01-16T16:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=634144"},"modified":"2023-01-16T16:28:01","modified_gmt":"2023-01-16T16:28:01","slug":"cutaneous-lupus-erythematosus-clinical-trials-a-drug-pipeline-analysis-report-2022-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cutaneous-lupus-erythematosus-clinical-trials-a-drug-pipeline-analysis-report-2022-delveinsight_634144.html","title":{"rendered":"Cutaneous Lupus Erythematosus Clinical Trials | A Drug Pipeline Analysis Report 2022 | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1673847429.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cutaneous Lupus Erythematosus Clinical Trials | A Drug Pipeline Analysis Report 2022 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1673847429.jpeg\" alt=\"Cutaneous Lupus Erythematosus Clinical Trials | A Drug Pipeline Analysis Report 2022 | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Cutaneous Lupus Erythematosus Pipeline Insights<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cCutaneous Lupus Erythematosus (CLE) \u2013 Pipeline Insight, 2023,\u201d report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Cutaneous Lupus Erythematosus (CLE) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\"><strong>Cutaneous Lupus Erythematosus Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&#8216;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-lupus-erythematosus-cle-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Cutaneous Lupus Erythematosus Pipeline Insight 2023<\/strong><\/a><strong>&#8216;<\/strong> report provides comprehensive global coverage of available, marketed, and pipeline Cutaneous Lupus Erythematosus therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cutaneous Lupus Erythematosus pipeline domain.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Cutaneous Lupus Erythematosus Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Various Cutaneous Lupus Erythematosus pipeline therapies are in various stages of development, and their anticipated acceptance in the Cutaneous Lupus Erythematosus market would significantly increase market revenue.&nbsp;<\/li>\n<li>Leading Cutaneous Lupus Erythematosus companies developing novel drug candidates to improve the Cutaneous Lupus Erythematosus treatment landscape include <strong>Sanofi, Bristol Myers Squibb, Merck, <\/strong>and others.<\/li>\n<li>Promising Cutaneous Lupus Erythematosus pipeline therapies in various stages of development include <strong>Eclitasertib, Deucravacitinib, Enpatoran, Afimetoran<\/strong>, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Cutaneous Lupus Erythematosus Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">The Cutaneous Lupus Erythematosus is an autoimmune skin disease that severely impairs quality of life.<\/p>\n<p style=\"text-align: justify;\">Cutaneous manifestations may be present as a single separate skin disease entity or may occur in the setting of a severe multiorgan autoimmune disease with a wide variety of manifestations (such as systemic lupus erythematosus. Also, patients initially diagnosed with isolated CLE may later progress to SLE.<\/p>\n<p style=\"text-align: justify;\">Similar to proposed etiologies for SLE, current theories discuss a multifactorial relationship leading to the development of cutaneous lupus, including genetic susceptibility, autoimmune induction, and immune system damage. Insights from genetic studies and environmental triggers in lupus pathogenesis implicate both innate and adaptive immune components.<\/p>\n<p style=\"text-align: justify;\">The pathophysiology of cutaneous lupus erythematosus (CLE) encompasses the complex interactions between genetics, the environment, and cells and their products. Central to the pathogenesis is the loss of immune tolerance and up regulation of the interferon-&alpha; (IFN-&alpha;) signaling.<\/p>\n<p style=\"text-align: justify;\"><strong>Cutaneous Lupus Erythematosus Pipeline Analysis: Drug Profile<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Eclitasertib: Sanofi<\/strong><\/p>\n<p style=\"text-align: justify;\">Eclitasertib formerly known as SAR443122 (Sanofi) is a small molecule of RIPK1 which is a critical signaling protein in the tumor necrosis factor receptor pathway and is a regulator of inflammation and cell death. Increased RIPK1 activity drives inflammation and cell necroptosis thoroughout the body and RIPK1 inhibition has been shown to have beneficial effects in preclinical models of many systemic inflammatory diseases. DNL758 is a potent and selective inhibitor of RIPK1 developed for the treatment of autoimmune diseases such as rheumatoid arthritis and peripheral inflammatory disease. Currently, it is in phase II clinical trial for CLE.<\/p>\n<p style=\"text-align: justify;\">Discover more about the emerging Cutaneous Lupus Erythematosus drugs @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-lupus-erythematosus-cle-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Cutaneous Lupus Erythematosus Treatment Drugs<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Cutaneous Lupus Erythematosus Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Sanofi<\/strong><\/li>\n<li><strong>Bristol Myers Squibb<\/strong><\/li>\n<li><strong>Merck<\/strong><\/li>\n<li><strong>And others<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cutaneous-lupus-erythematosus-cle-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Cutaneous Lupus Erythematosus Pipeline Therapies and Key Companies<\/strong><\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Eclitasertib<\/strong><\/li>\n<li><strong>Deucravacitinib<\/strong><\/li>\n<li><strong>Enpatoran<\/strong><\/li>\n<li><strong>Afimetoran<\/strong><\/li>\n<li><strong>And others<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Cutaneous Lupus Erythematosus Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>By development stage<\/strong><\/li>\n<li><strong>By product type<\/strong><\/li>\n<li><strong>By route of administration<\/strong><\/li>\n<li><strong>By molecule type<\/strong><\/li>\n<li><strong>By MOA type&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Scope of the Cutaneous Lupus Erythematosus Pipeline Report&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage<\/strong>:&nbsp;Global&nbsp;<\/li>\n<li><strong>Key Cutaneous Lupus Erythematosus Companies<\/strong>: Eclitasertib,Deucravacitinib,Enpatoran, Afimetoran, and others<\/li>\n<li><strong>Key Cutaneous Lupus Erythematosus Pipeline Therapies<\/strong>: Eclitasertib, Deucravacitinib, Enpatoran, Afimetoran, and others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Find out more about the Cutaneous Lupus Erythematosus treatment options in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-lupus-erythematosus-cle-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Cutaneous Lupus Erythematosus Clinical Trials<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Overview<\/p>\n<p style=\"text-align: justify;\">4. Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">5. Late-Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">6. Mid-Stage Products (Phase&nbsp; II)<\/p>\n<p style=\"text-align: justify;\">7. Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<p style=\"text-align: justify;\">8. Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">9. Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">11. Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Collaborations Assessment- Licensing \/ Partnering \/ Funding<\/p>\n<p style=\"text-align: justify;\">13. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">14. Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">15. Appendix<\/p>\n<p style=\"text-align: justify;\">16. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a sample report @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cutaneous-lupus-erythematosus-cle-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Cutaneous Lupus Erythematosus clinical trials&nbsp;<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cutaneous-lupus-erythematosus-clinical-trials-a-drug-pipeline-analysis-report-2022-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cutaneous-lupus-erythematosus-clinical-trials-a-drug-pipeline-analysis-report-2022-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cutaneous Lupus Erythematosus Pipeline Insights DelveInsight\u2019s, \u201cCutaneous Lupus Erythematosus (CLE) \u2013 Pipeline Insight, 2023,\u201d report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Cutaneous Lupus Erythematosus (CLE) pipeline landscape. It covers the pipeline drug profiles, including clinical &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cutaneous-lupus-erythematosus-clinical-trials-a-drug-pipeline-analysis-report-2022-delveinsight_634144.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-634144","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=634144"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634144\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=634144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=634144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=634144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}